Long	O
-	O
term	O
survival	O
outcome	O
after	O
postoperative	O
recurrence	B:C1458156
of	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
:	O
who	O
is	O
'	O
cured	O
'	O
from	O
postoperative	O
recurrence	O
?.	O

Long	O
-	O
term	O
survival	O
outcome	O
after	O
postoperative	O
recurrence	O
of	O
non-small	B:C0007131
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
:	O
who	O
is	O
'	O
cured	O
'	O
from	O
postoperative	O
recurrence	O
?.	O

Long	O
-	O
term	O
survival	O
outcome	O
after	O
postoperative	O
recurrence	O
of	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
:	O
who	O
is	O
'	O
cured	B:C0438113
'	O
from	O
postoperative	O
recurrence	O
?.	O

Long	O
-	O
term	O
survival	O
outcome	O
after	O
postoperative	O
recurrence	O
of	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
:	O
who	O
is	O
'	O
cured	O
'	O
from	O
postoperative	O
recurrence	B:C1458156
?.	O

Since	O
survival	O
after	O
postoperative	O
non-small	B:C0007131
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non-	O
small	I:C0007131
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
recurrence	O
is	O
extremely	O
poor	O
,	O
the	O
long	O
-	O
term	O
post	O
-	O
recurrence	O
outcomes	O
are	O
not	O
well	O
understood	O
.	O

Since	O
survival	O
after	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non-	B:C0007131
small	I:C0007131
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
recurrence	O
is	O
extremely	O
poor	O
,	O
the	O
long	O
-	O
term	O
post	O
-	O
recurrence	O
outcomes	O
are	O
not	O
well	O
understood	O
.	O

Since	O
survival	O
after	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non-	O
small	I:C0007131
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
recurrence	B:C1458156
is	O
extremely	O
poor	O
,	O
the	O
long	O
-	O
term	O
post	O
-	O
recurrence	O
outcomes	O
are	O
not	O
well	O
understood	O
.	O

Since	O
survival	O
after	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non-	O
small	I:C0007131
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
recurrence	O
is	O
extremely	O
poor	O
,	O
the	O
long	O
-	O
term	O
post	O
-	O
recurrence	B:C1458156
outcomes	O
are	O
not	O
well	O
understood	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	B:C0220825
the	O
long	O
-	O
term	O
post	O
-	O
recurrence	O
outcomes	O
and	O
clarify	O
who	O
are	O
possibly	O
'	O
cured	O
'	O
in	O
recent	O
clinical	O
practice	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
long	O
-	O
term	O
post	O
-	O
recurrence	B:C1458156
outcomes	O
and	O
clarify	O
who	O
are	O
possibly	O
'	O
cured	O
'	O
in	O
recent	O
clinical	O
practice	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
long	O
-	O
term	O
post	O
-	O
recurrence	O
outcomes	O
and	O
clarify	O
who	O
are	O
possibly	O
'	O
cured	B:C0438113
'	O
in	O
recent	O
clinical	O
practice	O
.	O

We	O
reviewed	O
the	O
medical	B:C0025102
records	I:C0025102
of	O
635	O
patients	O
who	O
developed	O
postoperative	O
recurrence	O
until	O
2012	O
after	O
R0	O
resection	I:C0728940
for	O
pathological	O
Stage	I:C0007131
IA	I:C0007131
-	I:C0007131
IIIA	I:C0007131
NSCLC	I:C0007131
between	O
1993	O
and	O
2006	O
.	O

We	O
reviewed	O
the	O
medical	O
records	I:C0025102
of	O
635	O
patients	O
who	O
developed	O
postoperative	O
recurrence	B:C1458156
until	O
2012	O
after	O
R0	O
resection	I:C0728940
for	O
pathological	O
Stage	I:C0007131
IA	I:C0007131
-	I:C0007131
IIIA	I:C0007131
NSCLC	I:C0007131
between	O
1993	O
and	O
2006	O
.	O

We	O
reviewed	O
the	O
medical	O
records	I:C0025102
of	O
635	O
patients	O
who	O
developed	O
postoperative	O
recurrence	O
until	O
2012	O
after	O
R0	B:C0728940
resection	I:C0728940
for	O
pathological	O
Stage	I:C0007131
IA	I:C0007131
-	I:C0007131
IIIA	I:C0007131
NSCLC	I:C0007131
between	O
1993	O
and	O
2006	O
.	O

We	O
reviewed	O
the	O
medical	O
records	I:C0025102
of	O
635	O
patients	O
who	O
developed	O
postoperative	O
recurrence	O
until	O
2012	O
after	O
R0	O
resection	I:C0728940
for	O
pathological	B:C0007131
Stage	I:C0007131
IA	I:C0007131
-	I:C0007131
IIIA	I:C0007131
NSCLC	I:C0007131
between	O
1993	O
and	O
2006	O
.	O

Factors	O
associated	O
with	O
post	O
-	O
recurrence	B:C1458156
surviva	O
l	O
(	O
PRS	O
)	O
and	O
the	O
characteristics	O
of	O
the	O
long	O
-	O
term	O
(	O
≥5	O
years	O
)	O
survivors	O
were	O
analysed	O
retrospectively	I:C0035363
.	O

Factors	O
associated	O
with	O
post	O
-	O
recurrence	O
surviva	O
l	O
(	O
PRS	O
)	O
and	O
the	O
characteristics	O
of	O
the	O
long	O
-	O
term	O
(	O
≥5	O
years	O
)	O
survivors	O
were	O
analysed	B:C0035363
retrospectively	I:C0035363
.	O

Multivariable	O
analysis	O
revealed	O
that	O
female	O
[	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
0.78	O
]	O
,	O
adenocarcinoma	B:C0001418
(	O
HR	O
=	O
0.77	O
)	O
,	O
locoregional	O
(	I:C0027643
only	I:C0027643
)	I:C0027643
recurrence	I:C0027643
(	O
HR	O
=	O
0.59	O
)	O
and	O
longer	O
recurrence	I:C2919733
-	I:C2919733
free	I:C2919733
survival	I:C2919733
(	O
HR	O
=	O
0.99	O
)	O
were	O
favourably	O
associated	O
with	O
PRS	O
.	O

Multivariable	O
analysis	O
revealed	O
that	O
female	O
[	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
0.78	O
]	O
,	O
adenocarcinoma	O
(	O
HR	O
=	O
0.77	O
)	O
,	O
locoregional	B:C0027643
(	I:C0027643
only	I:C0027643
)	I:C0027643
recurrence	I:C0027643
(	O
HR	O
=	O
0.59	O
)	O
and	O
longer	O
recurrence	I:C2919733
-	I:C2919733
free	I:C2919733
survival	I:C2919733
(	O
HR	O
=	O
0.99	O
)	O
were	O
favourably	O
associated	O
with	O
PRS	O
.	O

Multivariable	O
analysis	O
revealed	O
that	O
female	O
[	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
0.78	O
]	O
,	O
adenocarcinoma	O
(	O
HR	O
=	O
0.77	O
)	O
,	O
locoregional	O
(	I:C0027643
only	I:C0027643
)	I:C0027643
recurrence	I:C0027643
(	O
HR	O
=	O
0.59	O
)	O
and	O
longer	B:C2919733
recurrence	I:C2919733
-	I:C2919733
free	I:C2919733
survival	I:C2919733
(	O
HR	O
=	O
0.99	O
)	O
were	O
favourably	O
associated	O
with	O
PRS	O
.	O

A	O
total	O
of	O
51	O
patients	O
achieved	O
5	O
-	O
year	O
PRS	O
;	O
however	O
,	O
32	O
(	O
63	O
%	O
)	O
were	O
cancer	B:C0006826
-	O
bearing	O
patients	O
in	O
their	O
fifth	O
post	O
-	O
recurrent	O
year	O
who	O
were	O
mainly	O
treated	O
by	O
epidermal	O
growth	I:C1443775
factor	I:C1443775
receptor	I:C1443775
-	I:C1443775
tyrosine	I:C1443775
kinase	I:C1443775
inhibitor	I:C1443775
(	O
epidermal	O
growth	I:C1443775
factor	I:C1443775
receptor	I:C1443775
-	I:C1443775
tyrosine	I:C1443775
kinase	I:C1443775
inhibitor	I:C1443775
)	O
.	O

A	O
total	O
of	O
51	O
patients	O
achieved	O
5	O
-	O
year	O
PRS	O
;	O
however	O
,	O
32	O
(	O
63	O
%	O
)	O
were	O
cancer	O
-	O
bearing	O
patients	O
in	O
their	O
fifth	O
post	O
-	O
recurrent	O
year	O
who	O
were	O
mainly	O
treated	O
by	O
epidermal	B:C1443775
growth	I:C1443775
factor	I:C1443775
receptor	I:C1443775
-	I:C1443775
tyrosine	I:C1443775
kinase	I:C1443775
inhibitor	I:C1443775
(	O
epidermal	O
growth	I:C1443775
factor	I:C1443775
receptor	I:C1443775
-	I:C1443775
tyrosine	I:C1443775
kinase	I:C1443775
inhibitor	I:C1443775
)	O
.	O

A	O
total	O
of	O
51	O
patients	O
achieved	O
5	O
-	O
year	O
PRS	O
;	O
however	O
,	O
32	O
(	O
63	O
%	O
)	O
were	O
cancer	O
-	O
bearing	O
patients	O
in	O
their	O
fifth	O
post	O
-	O
recurrent	O
year	O
who	O
were	O
mainly	O
treated	O
by	O
epidermal	O
growth	I:C1443775
factor	I:C1443775
receptor	I:C1443775
-	I:C1443775
tyrosine	I:C1443775
kinase	I:C1443775
inhibitor	I:C1443775
(	O
epidermal	B:C1443775
growth	I:C1443775
factor	I:C1443775
receptor	I:C1443775
-	I:C1443775
tyrosine	I:C1443775
kinase	I:C1443775
inhibitor	I:C1443775
)	O
.	O

Subsequent	O
PRS	O
curves	B:C0681493
for	O
cancer	O
-	O
controlled	O
and	O
cancer	O
-	O
bearing	O
groups	O
were	O
different	O
(	O
8	O
-	O
year	O
PRS	O
:	O
94	O
%	O
vs	O
31	O
%	O
,	O
P	O
=	O
0.003	O
)	O
.	O

Subsequent	O
PRS	O
curves	O
for	O
cancer	B:C0006826
-	O
controlled	O
and	O
cancer	O
-	O
bearing	O
groups	O
were	O
different	O
(	O
8	O
-	O
year	O
PRS	O
:	O
94	O
%	O
vs	O
31	O
%	O
,	O
P	O
=	O
0.003	O
)	O
.	O

Subsequent	O
PRS	O
curves	O
for	O
cancer	O
-	O
controlled	B:C2911690
and	O
cancer	O
-	O
bearing	O
groups	O
were	O
different	O
(	O
8	O
-	O
year	O
PRS	O
:	O
94	O
%	O
vs	O
31	O
%	O
,	O
P	O
=	O
0.003	O
)	O
.	O

Subsequent	O
PRS	O
curves	O
for	O
cancer	O
-	O
controlled	O
and	O
cancer	B:C0006826
-	O
bearing	O
groups	O
were	O
different	O
(	O
8	O
-	O
year	O
PRS	O
:	O
94	O
%	O
vs	O
31	O
%	O
,	O
P	O
=	O
0.003	O
)	O
.	O

Among	O
19	O
cancer	B:C0006826
-	O
controlled	O
patients	O
in	O
their	O
fifth	O
post	O
-	O
recurrent	O
year	O
,	O
17	O
(	O
89	O
%	O
)	O
patients	O
initially	O
received	O
radical	O
local	I:C2986520
therapy	I:C2986520
for	O
their	O
recurrence	O
.	O

Among	O
19	O
cancer	O
-	O
controlled	B:C2911690
patients	O
in	O
their	O
fifth	O
post	O
-	O
recurrent	O
year	O
,	O
17	O
(	O
89	O
%	O
)	O
patients	O
initially	O
received	O
radical	O
local	I:C2986520
therapy	I:C2986520
for	O
their	O
recurrence	O
.	O

Among	O
19	O
cancer	O
-	O
controlled	O
patients	O
in	O
their	O
fifth	O
post	O
-	O
recurrent	O
year	O
,	O
17	O
(	O
89	O
%	O
)	O
patients	O
initially	O
received	O
radical	B:C2986520
local	I:C2986520
therapy	I:C2986520
for	O
their	O
recurrence	O
.	O

Among	O
19	O
cancer	O
-	O
controlled	O
patients	O
in	O
their	O
fifth	O
post	O
-	O
recurrent	O
year	O
,	O
17	O
(	O
89	O
%	O
)	O
patients	O
initially	O
received	O
radical	O
local	I:C2986520
therapy	I:C2986520
for	O
their	O
recurrence	B:C1458156
.	O

Two	O
-	O
thirds	O
of	O
5	O
-	O
year	O
survivors	O
after	O
postoperative	O
non-small	B:C0007131
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	O
had	O
a	O
cancer	O
-	O
bearing	O
status	O
and	O
showed	O
deteriorated	O
subsequent	O
survival	O
.	O

Two	O
-	O
thirds	O
of	O
5	O
-	O
year	O
survivors	O
after	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	B:C1458156
had	O
a	O
cancer	O
-	O
bearing	O
status	O
and	O
showed	O
deteriorated	O
subsequent	O
survival	O
.	O

Two	O
-	O
thirds	O
of	O
5	O
-	O
year	O
survivors	O
after	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	O
had	O
a	O
cancer	B:C0006826
-	O
bearing	O
status	O
and	O
showed	O
deteriorated	O
subsequent	O
survival	O
.	O

Two	O
-	O
thirds	O
of	O
5	O
-	O
year	O
survivors	O
after	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	O
had	O
a	O
cancer	O
-	O
bearing	O
status	O
and	O
showed	O
deteriorated	B:C1457868
subsequent	O
survival	O
.	O

Curability	O
of	O
postoperative	O
non-small	B:C0007131
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	O
should	O
be	O
evaluated	O
in	O
terms	O
of	O
the	O
'	O
cancer	O
-	O
controlled	O
'	O
status	O
,	O
and	O
'	O
cured	O
'	O
population	O
is	O
included	O
in	O
the	O
patients	O
who	O
are	O
'	O
cancer	O
controlled	O
'	O
at	O
the	O
fifth	O
post	O
-	O
recurrent	O
year	O
.	O

Curability	O
of	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	B:C1458156
should	O
be	O
evaluated	O
in	O
terms	O
of	O
the	O
'	O
cancer	O
-	O
controlled	O
'	O
status	O
,	O
and	O
'	O
cured	O
'	O
population	O
is	O
included	O
in	O
the	O
patients	O
who	O
are	O
'	O
cancer	O
controlled	O
'	O
at	O
the	O
fifth	O
post	O
-	O
recurrent	O
year	O
.	O

Curability	O
of	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	O
should	O
be	O
evaluated	B:C0220825
in	O
terms	O
of	O
the	O
'	O
cancer	O
-	O
controlled	O
'	O
status	O
,	O
and	O
'	O
cured	O
'	O
population	O
is	O
included	O
in	O
the	O
patients	O
who	O
are	O
'	O
cancer	O
controlled	O
'	O
at	O
the	O
fifth	O
post	O
-	O
recurrent	O
year	O
.	O

Curability	O
of	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	O
should	O
be	O
evaluated	O
in	O
terms	O
of	O
the	O
'	O
cancer	B:C0006826
-	O
controlled	O
'	O
status	O
,	O
and	O
'	O
cured	O
'	O
population	O
is	O
included	O
in	O
the	O
patients	O
who	O
are	O
'	O
cancer	O
controlled	O
'	O
at	O
the	O
fifth	O
post	O
-	O
recurrent	O
year	O
.	O

Curability	O
of	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	O
should	O
be	O
evaluated	O
in	O
terms	O
of	O
the	O
'	O
cancer	O
-	O
controlled	B:C2911690
'	O
status	O
,	O
and	O
'	O
cured	O
'	O
population	O
is	O
included	O
in	O
the	O
patients	O
who	O
are	O
'	O
cancer	O
controlled	O
'	O
at	O
the	O
fifth	O
post	O
-	O
recurrent	O
year	O
.	O

Curability	O
of	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	O
should	O
be	O
evaluated	O
in	O
terms	O
of	O
the	O
'	O
cancer	O
-	O
controlled	O
'	O
status	O
,	O
and	O
'	O
cured	B:C0438113
'	O
population	O
is	O
included	O
in	O
the	O
patients	O
who	O
are	O
'	O
cancer	O
controlled	O
'	O
at	O
the	O
fifth	O
post	O
-	O
recurrent	O
year	O
.	O

Curability	O
of	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	O
should	O
be	O
evaluated	O
in	O
terms	O
of	O
the	O
'	O
cancer	O
-	O
controlled	O
'	O
status	O
,	O
and	O
'	O
cured	O
'	O
population	B:C1257890
is	O
included	O
in	O
the	O
patients	O
who	O
are	O
'	O
cancer	O
controlled	O
'	O
at	O
the	O
fifth	O
post	O
-	O
recurrent	O
year	O
.	O

Curability	O
of	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	O
should	O
be	O
evaluated	O
in	O
terms	O
of	O
the	O
'	O
cancer	O
-	O
controlled	O
'	O
status	O
,	O
and	O
'	O
cured	O
'	O
population	O
is	O
included	O
in	O
the	O
patients	O
who	O
are	O
'	O
cancer	B:C0006826
controlled	O
'	O
at	O
the	O
fifth	O
post	O
-	O
recurrent	O
year	O
.	O

Curability	O
of	O
postoperative	O
non-small	O
-	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
recurrence	O
should	O
be	O
evaluated	O
in	O
terms	O
of	O
the	O
'	O
cancer	O
-	O
controlled	O
'	O
status	O
,	O
and	O
'	O
cured	O
'	O
population	O
is	O
included	O
in	O
the	O
patients	O
who	O
are	O
'	O
cancer	O
controlled	B:C2911690
'	O
at	O
the	O
fifth	O
post	O
-	O
recurrent	O
year	O
.	O

